Since 2000 to present, Hanahan and Weinberg have described the family of BCL2 proteins as hallmark of cancer and as a therapeutic target with mimicking molecules such as ABT-199, approved in 2015 for hematological malignancies as monotherapy and combination therapy [16]. The gene discussed is BCL2; the disease is hematologic disorder.